Condensed Consolidated Statements of Earnings (USD $) In Millions, except Per Share data, unless otherwise specified	3 Months Ended
	Sep. 30, 2013		Sep. 30, 2012
Income Statement [Abstract]
Revenue	$ 24,523		$ 25,889
Cost of products sold	23,259		24,730
Gross margin	1,264		1,159
Operating expenses:
Distribution, selling, general and administrative expenses	732		690
Restructuring and employee severance	11	[1]	5
Amortization and other acquisition-related costs	49		28
Impairments and loss on disposal of assets	0		1
Litigation (recoveries)/charges, net	1		(22)
Operating earnings	471		457
Other income, net	(4)		(8)
Interest expense, net	33		26
Earnings before income taxes and discontinued operations	442		439
Provision for income taxes	102		167
Earnings from continuing operations	340		272
Loss from discontinued operations, net of tax	(1)		(1)
Net earnings	$ 339		$ 271
Basic earnings per common share:
Continuing operations	$ 1.00		$ 0.80
Discontinued operations	$ 0.00		$ 0.00
Net basic earnings per common share	$ 1.00		$ 0.80
Diluted earnings per common share:
Continuing operations	$ 0.99		$ 0.79
Discontinued operations	$ 0.00		$ 0.00
Net diluted earnings per common share	$ 0.99		$ 0.79
Weighted-average number of common shares outstanding:
Basic	340		341
Diluted	344		344
Cash dividends declared per common share	$ 0.3025		$ 0.2375

[1] Includes $1 million of employee-related costs and $5 million of facility exit and other costs related to the restructuring within our Medical segment described further below.